A Multicenter, Retrospective Outcome Analysis of Vancomycin Area Under the Curve Versus Trough-Based Dosing Strategies in Patients With Burn OR Inhalational Injuries (MONITOR)

• Published in: Journal of burn care & research 2024-11, Vol.45 (6), p.1383-1389
• Main Authors: Santos, Richard M, Boyd, Allison N, Walroth, Todd A, Hall, Alexandria, King, Jessie, Ahiskali, Aileen, Walter, Ellen, Neumann, Nichole, Curry, Dominick, Hoyte, Brittany, Thomas, Wendy, Adams, Beatrice, Tran, Nicolas, Gleason, Vanessa M, Drabick, Zachary, DeWitt, Alexandra, Suarez, Justin, Prazak, Ann Marie B, Disney, Kathryn A, Hill, David M
• Format: Article
• Language: English
• Subjects: Adult; Anti-Bacterial Agents - administration & dosage; Area Under Curve; Burns; Burns, Inhalation - complications; Drug Monitoring - methods; Female; Humans; Male; Middle Aged; Retrospective Studies; Vancomycin - administration & dosage
• ISSN: 1559-047X; 1559-0488; 1559-0488
• DOI: 10.1093/jbcr/irae109

Abstract Vancomycin is a glycopeptide antibiotic that requires close therapeutic monitoring. Prolonged exposure to elevated concentrations increases risk for serious adverse effects such as nephrotoxicity. However, subtherapeutic concentrations may lead to bacterial resistance and clinical failure or death. The most recent Infectious Diseases Society of America publication regarding therapeutic monitoring of vancomycin recommends using area under the curve (AUC)-based monitoring to maximize clinical success. Despite the guideline recommendation for AUC-guided dosing, many institutions still use trough-only monitoring in their practices, including those caring for patients with acute burn injuries. Following burn injury, patients are at a higher risk for infections, multiorgan failure, and pharmacokinetic alterations. The primary objective of this multicenter retrospective study is to determine optimal therapeutic monitoring of vancomycin by comparing clinical success between AUC and trough-based monitoring in patients with burns. MONITOR was a multicenter, retrospective study of patients with thermal or inhalation injury admitted to one of 13 burn centers from January 1, 2017 to August 31, 2022 who received vancomycin. Demographic and clinical course data, including acute kidney injury (AKI) incidence and clinical success, were obtained. Patients were evaluated for clinical success and grouped according to method of monitoring and adjusting doses: AUC vs trough-based monitoring. Clinical success was a composite definition and lack of meeting any 1 of 5 criteria: (1) persistent infection, (2) relapse, (3) antibiotic failure (clinical worsening), (4) AKI, and (5) death. A total of 517 vancomycin courses were assessed from 485 patients. There was no difference in the rate of clinical success between AUC monitored and the trough-only monitored groups. Incidence of AKI was higher in the trough-only group; however, it was not statistically significant after controlling for renal function on admission, past medical history of chronic kidney disease, and concomitant nephrotoxins.